Tag: Maria Zannes

BioAffinity Lung Cancer Diagnostic Test Gets Closer to Market with Canadian Patent
Articles, Featured

BioAffinity Lung Cancer Diagnostic Test Gets Closer to Market with Canadian Patent

The San Antonio-based privately held biotech company bioAffinity Technologies announced Monday the Canadian Intellectual Property Office had awarded a patent for its proprietary CyPath© technology used in the early detection of cancer.The patent, titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” is bioAffinity’s third Canadian patent. bioAffinity’s intellectual property (IP) portfolio now consists of 51 awarded patents in 21 countries, with three additional patent applications filed in the U.S.The test is bioAffinity’s solution for the unusually high rate of false positives from computed tomography or CT scans used in early testing of suspected lung cancer. CyPath® Lung’s test uses flow cytometry and proprietary ...